Comparison of the cytotoxicity of two nitroheterociclic drugs (NHCD) towards transformed and non-transformed cells

被引:10
作者
Rossa, MM
Rocha-e-Silva, TAA
Terruggi, CHB
Tedesco, AC
Selistre-de-Araujo, HS
Borissevich, IE
Degterev, IA
机构
[1] Univ Fed Sao Carlos, Dept Physiol Sci, BR-13560 Sao Carlos, SP, Brazil
[2] Univ Sao Paulo, Dept Chem, BR-14049 Ribeirao Preto, Brazil
[3] Univ Sao Paulo, Dept Math & Phys, BR-14049 Ribeirao Preto, Brazil
[4] Russian Acad Sci, Inst Biochem Phys, Dept Chem & Biochem Kinet, Moscow, Russia
基金
巴西圣保罗研究基金会;
关键词
cytotoxicity; nitroheterocyclic drug; lympholeukaemia P388; erythroleukaemia K562; fibroblasts NIH3T3;
D O I
10.1016/S1043-6618(03)00183-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cytotoxicity of two nitroheterocyclic compounds (NHCD), Nitracrine, 1-nitro-9(3'3-dimethylaminopropylamino) acridine (Polfa, Poland) and Quinifuryl, 2-(5'-nitro-2-furanyl) ethenyl-4-{N-[4-(N,N-diethylamino)-1'-methylbutyl] carbamoyl}quinoline (Dr. N. M. Sukhova, Institute of Organic Synthesis, Riga, Latvian Republic), towards two lines of leukaemic cells and a line of non-transformed cells, was determined under normoxia conditions. Although both drugs showed significant cytotoxicity to all cell lines (LC50 for 24 h, less than or equal to2 muM) with that of Nitracrine exceeding Quinifuryl, their toxicity towards murine leukaemia P388 was substantially higher, compared to murine fibroblasts NIH3T3. In addition, the rate of cell death was also two- to three-fold higher in case of P388 cells versus NIH3T3. Interestingly, human erythroleukaemia K562 cells were shown to uptake the drugs 10 min after their addition to the tissue culture medium, while the LC50 values were reached after a substantial delay of 3 h. This delay might be due to the intracellular transformation of drugs required for cell killing. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:369 / 375
页数:7
相关论文
共 17 条
[1]  
Blatun L. A., 1999, Antibiotiki i Khimioterapiya, V44, P25
[2]  
DEGTEREV IA, 1986, KHIM FARM ZH+, V20, P412
[3]  
DEGTEREV IA, 1990, KHIM FARM ZH+, V24, P9
[4]   NITRACRINE AND ITS CONGENERS - AN OVERVIEW [J].
GNIAZDOWSKI, M ;
SZMIGIERO, L .
GENERAL PHARMACOLOGY, 1995, 26 (03) :473-481
[5]  
GNIAZDOWSKI M, 1979, ANTIBIOTICS V2, P275
[6]   Products of metabolic activation of the antitumor drug ledakrin (Nitracrine) in vitro [J].
Gorlewska, K ;
Mazerska, Z ;
Sowinski, P ;
Konopa, J .
CHEMICAL RESEARCH IN TOXICOLOGY, 2001, 14 (01) :1-10
[7]  
JOSEPHY PD, 1985, BIOACTIVATION FOREIG, P161
[8]   PROPERTIES OF K562 CELL LINE, DERIVED FROM A PATIENT WITH CHRONIC MYELOID LEUKEMIA [J].
KLEIN, E ;
BENBASSAT, H ;
NEUMANN, H ;
RALPH, P ;
ZEUTHEN, J ;
POLLIACK, A ;
VANKY, F .
INTERNATIONAL JOURNAL OF CANCER, 1976, 18 (04) :421-431
[9]   FEASIBILITY OF A HIGH-FLUX ANTICANCER DRUG SCREEN USING A DIVERSE PANEL OF CULTURED HUMAN TUMOR-CELL LINES [J].
MONKS, A ;
SCUDIERO, D ;
SKEHAN, P ;
SHOEMAKER, R ;
PAULL, K ;
VISTICA, D ;
HOSE, C ;
LANGLEY, J ;
CRONISE, P ;
VAIGROWOLFF, A ;
GRAYGOODRICH, M ;
CAMPBELL, H ;
MAYO, J ;
BOYD, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (11) :757-766